Acute Coronary Syndrome (ACS) remains a leading cause of mortality and morbidity worldwide, necessitating the continuous evolution of its management strategies. This article aims to shed light on contemporary approaches to optimize patient outcomes in ACS management.
Pharmacotherapy forms the cornerstone of ACS management. Dual antiplatelet therapy (DAPT) comprising aspirin and a P2Y12 inhibitor remains the mainstay. Recent evidence suggests a shortened DAPT duration coupled with potent P2Y12 inhibitors like ticagrelor or prasugrel can reduce bleeding risks without compromising ischemic benefits. Additionally, novel anticoagulants like rivaroxaban have shown promising results in reducing adverse cardiac events in ACS patients.
Timely reperfusion, primarily through percutaneous coronary intervention (PCI), significantly improves survival in ACS. Advances in PCI techniques, including the use of drug-eluting stents and intravascular imaging, have improved its success rate. Furthermore, emphasis on 'door-to-balloon' time reduction and systems of care optimization have enhanced patient outcomes.
Non-invasive testing plays a pivotal role in risk stratification and guiding management in ACS. High-sensitivity cardiac troponin assays and novel biomarkers like copeptin and heart-type fatty acid-binding protein (H-FABP) have improved early diagnosis. Imaging modalities like coronary CT angiography and cardiac magnetic resonance imaging provide valuable prognostic information.
Secondary prevention measures including lifestyle modifications, cardiac rehabilitation, and optimal control of risk factors like hypertension and dyslipidemia are crucial in preventing recurrent events and improving long-term outcomes in ACS patients.
Contemporary ACS management involves a multi-faceted approach incorporating evidence-based pharmacotherapy, optimized reperfusion strategies, non-invasive testing, and robust secondary prevention measures. As our understanding of ACS evolves, it is imperative to continuously update our management strategies to improve patient outcomes.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation